Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870279 | 0.83 | PPARG (0.55) | PPARAPPARGPSMB5 | |
| SCHEMBL4043400 | 0.79 | PSMB5 (0.56) | PPARAPPARGPSMB5 | |
| SCHEMBL4043403 | 0.79 | PSMB5 (0.56) | PPARAPPARGPSMB5 | |
| SCHEMBL7541726 | 0.76 | PPARG (0.63) | PPARAPPARGPSMB5 | |
| SCHEMBL4704738 | 0.76 | MME (0.47) | PPARAPPARGPSMB5FFAR1 | |
| SCHEMBL7541731 | 0.76 | PPARG (0.63) | PPARAPPARGPSMB5 | |
| SCHEMBL5870584 | 0.75 | PPARG (0.44) | PPARAPPARGLTA4HPSMB5FFAR1 | |
| SCHEMBL5870622 | 0.75 | PPARG (0.44) | PPARAPPARGLTA4HPSMB5FFAR1 | |
| SCHEMBL5870215 | 0.75 | PSEN1 (0.48) | PPARAPPARGFFAR1 | |
| SCHEMBL7545793 | 0.74 | LDHA (0.53) | PPARAPPARGFFAR1HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1358174-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057248-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | PPARA 4641/4885PPARG 4463/4885LTA4H 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.